I could kind of understand if they reject emergency approval without a placebo arm. I wouldn't agree with it, but I could see how FDA, with the interest of BP in mind could convince themselves to that decision. However, if the preliminary analysis of the p2b/3 produces excellent results and it still gets rejected, then I would have to acknowledge the possibility that every indication moving forward would get the same dog shit treatment.